Liquidia (LQDA) Q3 2026 earnings review
Liquidia settles its patent war, but forfeits a major market
Liquidia ended its legal war over Yutrepia, its inhaled lung-disease drug, by giving up one of its two approved markets. Third-quarter product sales jumped by $52 million from the previous quarter to $223 million, generating $112 million in new cash. However, after losing a September patent ruling to rival United Therapeutics, chief executive Roger Jeffs agreed to pay $381 million and remove the lung-scarring indication from Yutrepia's label.
| Yutrepia net product sales | $222.7M +31% from last quarter (+$52.4M) |
|---|---|
| Paid patient demand | $212.2M 95% of net product sales |
| Net legal settlement cost | $380.7M $396.1M cash on hand at quarter-end |
| October daily referral rate | >75% of Q3 after halting PH-ILD promotion |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because solving the legal threat to the whole business came at the cost of a major growth engine. Settling all six lawsuits removes the danger of a total sales ban in pulmonary arterial hypertension, and the $396 million cash pile covers the payout. The bad news: stopping promotion for lung-scarring hypertension cut October's daily referral rate to just over 75% of the third-quarter pace, and the release dropped its cumulative patient-start disclosure.
The question now is whether Yutrepia can keep adding $40 million to $50 million in quarterly sales from arterial hypertension alone. Either repeat prescribing and record October shipments keep revenue climbing toward the old $1 billion target for 2027, or the 25% drop in daily referrals slows fourth-quarter sales additions. Fourth-quarter paid patient demand will tell.
🐂 Bull Case
Yutrepia Added a Record $52 Million in Sales
Liquidia makes Yutrepia, an inhaled dry-powder drug for high blood pressure in the lungs. After adding roughly $40 million in quarterly sales for three straight periods, Yutrepia net product sales jumped by $52.4 million from last quarter to $222.7 million. For the first time, the biopharmaceutical group disclosed that $212.2 million of that total came from paid patient demand, excluding free vouchers and access programmes.
- Yutrepia net product sales: $222.7 million, up 30.7% from last quarter
- Paid patient demand: $212.2 million, or 95.3% of net product sales by our math
- Prescriber base: 1,300 doctors through October, up by 200 since July
- Repeat prescribing: more than 30% of doctors have written prescriptions for at least five patients
The paid demand figure matters because it proves that revenue comes from paying patients rather than one-time channel stocking. In addition, total patient shipments in October reached their highest monthly level since launch, and doctors converted more than 87% of monthly referrals into patient starts, up from 85% in prior quarters.
What to watch: fourth-quarter paid patient demand in the next earnings release. A sequential rise during the first full quarter without promotion for lung-scarring hypertension would show that existing patients and core arterial hypertension starts can still drive growth.
Settlement Protects Core Sales and Cash Covers It
For more than a year, competitor United Therapeutics sued to block Yutrepia from the market. On October 13, Liquidia signed a global settlement that resolved all six pending lawsuits between the two companies. Under the deal, Yutrepia stays on the market "without disruption, and no patients are required to discontinue" their treatment.
The drugmaker agreed to pay a net $380.7 million across multiple installments in 2026 and 2027, which triggered a $389.7 million accounting charge this quarter. Because the business added $111.9 million to its cash balance in the third quarter alone, ending September with $396.1 million, Liquidia already holds enough cash on hand to cover the entire net settlement bill without raising money from investors.
What to watch: the installment payment schedule in the third-quarter filing. It will show how much cash leaves the balance sheet in the fourth quarter versus next year.
Slowing Overhead Growth Lifted Operating Margin
Excluding the one-off $389.7 million legal settlement charge, operating income reached $126.2 million by our math, or 56.0% of revenue, up 6.2 percentage points from last quarter. The margin expanded because selling, general and administrative expenses — sales reps, marketing and overhead — grew less than 3% from the second quarter and fell by 7.3 percentage points of revenue to 26.2%.
Research and development spending rose from $17.2 million in the second quarter to $25.3 million, or 11.2% of revenue, as the team advanced its L606 clinical trials. Even with that 1.2-point research step-up, the wider revenue base absorbed the extra clinical costs.
What to watch: fourth-quarter research and development spending. By our math, the prior second-half plan leaves $34.2 million of research spending for the fourth quarter, which will test whether operating margin can stay above 50%.
🐻 Bear Case
Losing the Lung-Scarring Label Cut October Referrals
"With the litigation now fully resolved, and YUTREPIA’s commercial availability secure, we can fully focus on cementing the value of YUTREPIA through Phase 4 studies in PAH," chief executive Roger Jeffs said. Pulmonary arterial hypertension (PAH) is high blood pressure in the arteries of the lungs. Jeffs framed the legal peace as a clean path forward, but the settlement came after a federal court ruled on September 30 that Yutrepia infringed a United Therapeutics patent covering pulmonary hypertension associated with interstitial lung disease (PH-ILD), a lung-scarring condition.
Because of that loss, Liquidia filed "to remove the PH-ILD indication from YUTREPIA’s label, and has ceased promoting YUTREPIA for PH-ILD". From launch through September, more than 60% of referrals carried a PAH diagnosis, which means up to 40% came from the PH-ILD market the company just exited. The commercial impact showed up right away: in October, the daily referral rate dropped to just over 75% of the third-quarter pace.
What to watch: whether management reaffirms its target of more than $1 billion in 2027 net revenue on the conference call. Silence or a cut would show that losing PH-ILD promotion slows the launch trajectory below the old plan.
Liquidia Stopped Reporting Cumulative Patient Starts
In each of the first five quarters after Yutrepia's launch, the press release gave the cumulative number of unique patient prescriptions and cumulative patient starts, which stood at 5,900 and 5,000 at the end of July. This quarter's release omitted both figures and replaced them with percentage ratios, such as October daily referrals running above 75% of the third-quarter rate.
The drugmaker already withholds the number of active patients still taking the medicine and the patient drop-off rate. Removing the cumulative start count right as referrals slow in October makes it impossible to calculate how many new patients started treatment this quarter or how much revenue each patient generates.
What to watch: the conference call remarks and quarterly filing for an exact patient start count through October. If executives do not give the number on the call, outside investors will lose their main volume tracker.
Settlement Leaves Pipeline Drugs Open to Lawsuits
Because Yutrepia can no longer be promoted for PH-ILD, Liquidia relies on L606 — an investigational twice-daily mist version of treprostinil — to recapture that lung-scarring market, alongside new Yutrepia studies in Raynaud's phenomenon (SSc-RP, a blood-flow disorder) and chronic obstructive pulmonary disease (PH-COPD). However, the release warns that "the settlement agreement does not extend to indications other than PAH or to new treprostinil-containing products".
That exclusion means United Therapeutics can still assert its patents against L606 or any new Yutrepia uses. In addition, the settlement ended the Sandoz promotion agreement in October, permanently eliminating $2.6 million in quarterly service revenue.
What to watch: any new patent infringement filings by United Therapeutics as L606 advances its pivotal Re-Spire study toward completion in 2029. A lawsuit against L606 would recreate the legal overhang for the company's second drug.
Risks this quarter didn't answer
Six standing business and financial concerns received no update in the third-quarter earnings release.
- Single-product reliance: Yutrepia now represents 100% of ongoing revenue after the Sandoz promotion deal ended in October, and L606 will not finish pivotal trials until 2029.
- Competitor pipeline: the release gives no read on United Therapeutics' rival inhalers or payer contracting pressure on drug rebates.
- Manufacturing concentration: reliance on single-source suppliers and the late-2026 lease start for the second Morrisville factory awaits the quarterly filing's footnotes.
- Tax rate path: Liquidia booked a $30.1 million tax benefit on the settlement loss; the cash tax rate once net operating losses run out remains unquantified.
- Royalty debt acceleration: the HealthCare Royalty Partners financing still carries an acceleration clause if a therapeutically equivalent inhaled drug wins approval.
💲 Other KPIs
Cash rose by $111.9 million from last quarter, up from a $61.4 million addition in the second quarter and $32.1 million in the first. This balance sits prior to paying the $380.7 million net litigation settlement across 2026 and 2027, leaving $15.4 million in excess of the total settlement bill before fourth-quarter cash generation.
Total liabilities more than doubled from $326.8 million in June, increasing 116.8% in a single quarter. The jump reflects the $389.7 million net litigation settlement accrual, which includes $330.4 million payable to United Therapeutics and $60.3 million payable to antitrust litigation parties, pushing stockholders' equity into a $25.4 million deficit.
Adjusted EBITDA — earnings before interest, taxes, depreciation, stock-based pay and the legal settlement charge — rose 45.9% from $96.3 million in the second quarter. It marks the fifth straight quarter of sequential growth since Yutrepia launched, up from $10.1 million a year ago.
🔮 Guidance
Unchanged. Liquidia initiated the open-label LTI-403 study on schedule in the third quarter to test switching adults with PAH from oral selexipag to Yutrepia, and now sets primary completion for the second quarter of 2027.
Unchanged. The company still plans to start the open-label SPRINT trial in the fourth quarter of 2026 to measure pulmonary vascular resistance after 16 weeks of Yutrepia treatment.
Raised. The drugmaker enrolled its first patient in the RE-WARM dose-finding study for systemic sclerosis-associated Raynaud's phenomenon ahead of its fourth-quarter target after winning FDA Fast Track status in September, and expects primary completion in the first quarter of 2027.
Unchanged. Management gave specific completion years for the global placebo-controlled Re-Spire trial in PH-ILD, targeting full enrollment in 2028 and primary study completion in 2029, while planning to start L606 trials in PAH and PH-COPD in 2027.
❓ Key Questions
Does the $1 billion 2027 revenue target still stand?
Prior to losing the PH-ILD label, executives expressed confidence in exceeding $1 billion in 2027 net revenue. With October daily referrals down by nearly a quarter, investors need to know whether PAH alone can still reach that mark.
How many cumulative and active patients are on Yutrepia?
The release dropped the cumulative patient starts and prescription counts after reporting them for five straight quarters. Without cumulative starts or an active-patient count, outsiders cannot separate new patient additions from patient drop-offs.
What share of third-quarter revenue came from PH-ILD patients?
More than 60% of cumulative referrals through September carried a PAH diagnosis, rising to over 70% in September. Management has not disclosed how much of the $222.7 million in third-quarter sales came from the PH-ILD market it just stopped promoting.
What is the exact payment schedule for the $380.7M settlement?
Liquidia agreed to pay net $380.7 million in multiple installments across 2026 and 2027. The timing of those cash outflows determines how much liquidity remains each quarter alongside rising clinical trial costs.